US Patent

US11844837 — Compositions of a polyorthoester and an organic acid excipient

Method of Use · Assigned to Heron Therapeutics LLC · Expires 2036-04-21 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent describes delivery systems and compositions made of a biodegradable polymer, an organic acid, and a basic drug.

USPTO Abstract

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3417`	—	Bupivacaine Hydrochloride And Epinephrine
`U-3417`	—	Bupivacaine Hydrochloride And Epinephrine
`U-3417`	—	Bupivacaine Hydrochloride And Epinephrine
`U-3417`	—	Bupivacaine Hydrochloride And Epinephrine

Patent Metadata

Patent number: US11844837
Jurisdiction: US
Classification: Method of Use
Expires: 2036-04-21
Drug substance claim: No
Drug product claim: No
Assignee: Heron Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.